logo

For the Inventor, By the Inventor

Saint Nom la Breteche, France

Michael R Myers

This inventor holds 7 USPTO granted patents. Top assignee: Aventis Pharma S.a.. Active years: 2002-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael R Myers. Retrieved from https://idiyas.com/inventor/michael-r-myers-qfhvvdc7

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 7

% Patents Active = 28.6

Average Co-Inventor Count = 7.0

ph-index = 5

Forward Citations = 146(Granted Patents)


Company Filing History:

goldMedal7 out of 377 
 
Aventis Pharma S.a.
 patents

Years Active: 2002-2010

Loading Chart...
7 patents (USPTO):Explore Patents
1. 7741316 - Pharmacological uses of azetidine derivatives (2010-06-22),
2. 7132414 - Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation (2006-11-07),
3. 6872717 - Pharmacological uses of azetidine derivatives (2005-03-29),
4. 6734176 - Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation (2004-05-11),
5. 6566356 - Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation (2003-05-20),
6. 6479479 - Azetidine derivatives, their preparation and pharmaceutical compositions containing them (2002-11-12),
7. 6355631 - Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation (2002-03-12),

Title: Michael R. Myers: Innovator in Pharmacological Research

Introduction

Michael R. Myers is a distinguished inventor based in Saint Nom la Breteche, France. He has made significant contributions to the field of pharmacology, particularly in the development of treatments for neurological disorders. With a total of seven patents to his name, Myers has established himself as a key figure in pharmaceutical innovation.

Latest Patents

Among his latest patents, one notable invention is focused on the pharmacological uses of azetidine derivatives. This method aims to treat or prevent Alzheimer's disease, Parkinson's disease, and schizophrenia. The treatment involves administering a specific compound to patients in need. Another significant patent involves pharmaceutical compositions containing 3-aminoazetidine derivatives. This invention relates to the preparation and use of these compounds in treating various disorders of the nervous system.

Career Highlights

Michael R. Myers is currently associated with Aventis Pharma S.A., where he continues to advance his research and development efforts. His work has been instrumental in creating innovative solutions for complex health issues, particularly those affecting the nervous system.

Collaborations

Throughout his career, Myers has collaborated with notable colleagues, including Daniel Achard and Jean Bouquerel. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in pharmacology.

Conclusion

Michael R. Myers exemplifies the spirit of innovation in the

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…